Patent Application
20200024321
The present invention pertains to a process for the large scale preparation of a biologically active recombinant peptide in a suitable host by overexpressing it as a concatemer having specific intervening Kex2 protease and Carboxypeptidase B cleavage sites separating each monomer. Sequential digestion of the expressed multimer by Kex2 protease followed by carboxypeptidase yields the desired monomeric peptide in large quantities.
Glucagon-like peptide-1 (GLP-1), a product of the glucagon gene, is an important gut hormone known to be the most potent insulinotropic substance. It is effective in stimulating insulin secretion in non-insulin dependent diabetes mellitus (NIDDM) patients. Furthermore, it potently inhibits glucagon secretion and due to these combined actions it has demonstrated significant blood glucose lowering effects particularly in patients with NIDDM. A number of FDA approved GLP-1 analogs are available, for instance, exenatide (Byetta in 2005, Bydureon in 2012), albiglutide (Tanzeum in 2014), dulaglutide (Trulicity in 2014) and liraglutide (Victoza in 2010, Saxenda in 2014).
Liraglutide is an acylated derivative of the GLP-1 (7-37) that shares a 97% sequence homology to the naturally occurring human hormone by virtue of a substitution of lysine at position 34 by arginine (K 34R). It contains a palmitoylated glutamate spacer attached to e-amino group of Lys26. The molecular formula of liraglutide is C172H265N43O51 while its molecular weight is 3751.2 daltons.
Liraglutide was developed by Novo Nordisk (U.S. Pat. No. 6,268,343) as Victoza (FDA approval 2010) to improve glycemic control in adults with type 2 diabetes mellitus and as Saxenda (FDA approval 2014) for chronic weight management in obese adults in the presence of at least one weight-related comorbid condition. The peptide precursor of liraglutide was produced by recombinant expression in Saccharomyces cerevisiae.
Several chemical (solid-phase syntheses) and biological (recombinant) syntheses for the preparation of GLP-1 analogues have been described in the art.
Recombinant synthesis in simple hosts like E. coli or yeasts are plagued by either poor expression levels or high expression levels with scanty yields attributed to host degradative enzymes. This degradation has been overcome by the use of fusion tags or carriers like the histidine-tag, glutathione-S-transferase (GST), maltose binding protein, NusA, thioredoxin (TRX), small ubiquitin-like modifier(SUMO) and ubiquitin (Ub), which brings about safe delivery of the desired peptide. Expression of large fusion protein tags often leads to drop in overall yields and recovery of protein of interest, which is obtained after removal of the high molecular weight fusion partner from the peptides. Excision of the fusion tags by cleavage at specific sites either chemically (like CNBr) or by enzymatic methods confers inherent advantages pertaining to enhanced selectivity and specificity along with benign reaction conditions that lowers side reactions and helps to maximize yields.
U.S. Pat. No. 8,796,431 describes a process for producing a fusion peptide comprising an affinity tag, a cleavable tag and the peptide of interest (GLP-1 and liraglutide). Despite the ease and efficiency of purification via affinity chromatography, reduced overall yields were obtained.
The limitation of the fusion or carrier peptide approach has been overcome by expressing multiple repeats of the peptide of interest (POI) with intervening cleavage sites leading to respectable yields.
Thus, WO95/17510 discloses a method for producing GLP-1 (7-36) or its analogs using more than two consecutive DNA sequences coding for GLP-1 (7-36) which after expression was digested with enzymes like trypsin or clostripain and carboxypeptidase B or Y under suitable conditions to provide monomers. A similar strategy has been described in U.S. Pat. No. 7,829,307 for the preparation of GLP-2 peptides. U.S. Pat. No. 5,506,120 describes a process for preparing a concatemer of vasointestinal peptide (VIP) having alternate excisable basic dipeptide sites that was expressed in a mutant B. subtilis strain displaying less than 3% protease activity compared to the wild strain.
The present invention involves the preparation of the liraglutide peptide precursor K34R GLP-1 (7-37), the mGLP peptide, in a suitable host, such as E. coli, B. subtilis etc using its concatemer with intervening excision sites, thus reducing the total number of steps in obtaining the POI. Further, excision at the alternating di peptide cleavage sites simultaneously with kex2 protease and carboxypeptidase B allow preparation of the authentic peptide precursor without any extra terminal amino acid.
In an embodiment, a concatemeric DNA construct for producing a peptide of SEQ ID 1, wherein the concatemeric DNA construct comprises:
In an embodiment, expressing the concatemeric DNA construct to obtain multimers of peptide of SEQ ID 1 in the form of inclusion bodies.
In another embodiment, a process for producing a peptide of SEQ ID 1, the process comprising:
In a further embodiment, cloning the concatemer in a prokaryotic or eukaryotic host using two or more inducers.
In a further embodiment, contacting the multimers of peptide of SEQ ID 1 simultaneously or sequentially with at least two proteases to obtain the peptide of SEQ ID 1.
In an embodiment, the present invention provides a process for producing the peptide precursor for liraglutide on a large scale by using its concatemer having alternate dipeptide Lys-Arg (K R) cleavage sites, excisable by sequential action of specific enzymes to release the biologically active monomer.
In another embodiment, a concatemeric gene containing 9-15 repeats of the gene for liraglutide precursor peptide having alternate K R sites was synthesized and then cloned into a suitable expression vector. Transformation of E. coli with the recombinant vector and its expression led to the peptide multimer as inclusion bodies.
In a further embodiment, the invention relates to a process for producing a biologically active GLP-1 (7-37), the process comprising:
As used herein, the term ‘small peptide_or ‘peptides_refers to those having molecular weight ranging from about 2 to 10 kDa, used as a bio-therapeutic or for diagnostic and research purposes, wherein the preferred peptide is the peptide precursor for liraglutide, namely, K34R GLP-1 (7-37), the mGLP. The above-mentioned precursor contains amino acid residues from 7 to 37 of the glucagon-like peptide-1 (GLP-1) wherein the Lys at position 34 in the naturally occurring GLP-1 is substituted by Arg.
Especially in case of low molecular weight peptides, like the desired peptide, recombinant technology techniques are used to further enhance yield by expressing tandem gene repeats of the desired peptide that have been referred to herein as :concatemer’ which is defined as a long continuous DNA molecule that contains serially linked multiple copies of a smaller DNA sequence that codes for a monomer of the desired peptide. A concatemer may comprise 2-20 repeats of the monomer.
In the concatemer, individual DNA sequences coding for the monomer were separated by short cleavable dipeptidyl spacer sequences between every monomeric units. Many inactive precursors of bioactive peptides contain processing signal sequences made of a pair of basic dipeptides like Arg-Arg, Lys-Lys, Arg-Lys, Lys-Arg that are processed by specific enzymes to give the physiologically active peptides. Several proteases are known to show strict primary and secondary specificities to the above mentioned dipeptides and cleave precisely at the C- or N-terminus of or between the dipeptide. Particularly, this method is effective only when the desired peptide does not contain such a sequence recognizable by the excising enzyme. The preferred peptide K34R GLP-1 (7-37) being free of such basic di peptides in its sequence is an excellent candidate for the above method.
In the present invention, a concatemeric gene construct possessing intervening codons for the requisite excision sites was synthesized and inserted into a suitable expression vector. As used herein, the term ‘expression vector_refers to a DNA molecule used as a vehicle to artificially carry foreign genetic material into bacterial cell, where it can be replicated and over-expressed.
The concatemeric gene construct was placed downstream of a T7 promoter in the expression vector. As used herein, the term ‘promoter_refers to a regulatory region of DNA usually located upstream of the inserted gene of interest, providing a control point for regulated gene transcription.
For cloning, suitable host cells such as E. coli host cells were transformed by the recombinant expression vector. As used herein, an ‘E. coli host_refers to E. coli strains ranging from BL21, BL21 DE3, BL21 Al and others which are routinely used for expression of recombinant proteins.
In another embodiment, the expressed concatemer was ‘isolated from the cell culture_by one or more steps including lysing of the cells using a homogenizer or a cell press, centrifugation of the resulting homogenate to obtain the target protein as insoluble aggregates.
In an embodiment, the concatemer was expressed as insoluble inclusion bodies that inherently possessed specific dipeptide sites which, upon digestion with specific enzymes, released the desired monomeric peptide precursors. In a preferred embodiment, the intervening Lys-Arg (K R) sites were cleaved using sequential action of kex2 protease and carboxypeptidase B.
In another embodiment, the invention relates to a process of producing a biologically active GLP-1 (7-37), the process comprising:
Experimental Section
K34R GLP-1 (7-37) was produced by recombinant DNA technology using genetically engineered E. coli cells. The E. coli cells were cultured and concatemers of the peptide precursor for liraglutide were obtained in the form of inclusion bodies, post induction. Inclusion bodies were processed by (subjected to) solubilization and sequential digestion to release the biologically active K34RGL P-1 (7-37) monomers.
The nucleotide sequence derived from the amino acid sequence for K34R GLP-1 (7-37) monomer (SEQ ID 1) was codon optimized for E. coli (SEQ ID 2) to synthesize the K34R GLP-1 (7-37) concatemer (SEQ ID 3) as illustrated in
The concatemer was synthesized and cloned into pET24a vector within the cloning sites, Nde I and Hind III. The vector pET24a possesses a strong T7 promoter for the expression of recombinant protein and a kanamycin resistance gene for selection and screening. The digested pET24a vector was ligated to the concatemer to provide the recombinant vector which was used to transform the E. coli host. The clones were screened by colony PCR and confirmed by restriction digestion with Nde I and Hind III and sequence analysis of the clone.
E. coli BL21 A1 cell line was used as the expression host. Other cell lines that may be used include BL21 DE3 or any other cell line that contains the T7 RNA polymerase. BL21 A1 cells transformed with the recombinant pET24a-GLP concatemer were induced (OD600˜1) with 13 mM arabinose and 1 mM IPTG. The cells were harvested about 4 hours after induction. Determination of expression levels by SDS PAGE analysis of the whole cell lysate showed the presence of a ˜35 kDa band for the multimeric precursor peptide (
The cell lysate was further homogenized by sonication and centrifuged to separate inclusion bodies and soluble fractions. A bout 0.125 g inclusion bodies were weighed and dissolved in 3.0 mL of 2% SDS and 1.2 mL of 500 mM HEPES buffer (pH 7.5) diluted with milliQ water to make the volume to 6 mL. Complete solubilization (15-30 min) of the inclusion bodies was carried out by vortexing followed by centrifugation to obtain the K34R GLP-1 (7-37) multimer molecules in the supernatant. The solubilized inclusion bodies were further diluted 10 times in a final buffer composition of 50 mM HEPES, pH 7.5, 10 mM CaCl2 and 2% Triton-X -100.
Protease digestion studies were carried out independently using 2.5, 5 and 20 ι g of kex2 protease (kex2 P) per mg of solubilized inclusion bodies for 20-28 h at room temperature. A band at 3 kDa observed by SDS PAGE (
A similar experiment was carried out with digestion of solubilized inclusion bodies with 5, 10 and 20 ι g of kex2 protease per mg of solubilized inclusion bodies for 16 h at room temperature. This was followed by further addition of 5 ι L (0.67 U/mL carboxypeptidase B (CPB) per mg of solubilized inclusion bodies at 37 éC for 2 hours. The resulting digestion mixture was analyzed by SDS PAGE (
Lane 1: Molecular weight marker
Lane 2: Uninduced whole cell lysate of mGLP concatemer
Lane 3: Induced whole cell lysate of mGLP concatemer clone #1
Lane 4: Induced whole cell lysate of mGLP concatemer clone #2
Lane 1: Molecular weight marker
Lane 2 − mGLP (concatemer) undigested_20 h
Lane 3 − mGLP (concatemer) undigested_24 h
Lane 4 − mGLP (concatemer) undigested_28 h
Lane 5 − mGLP (concatemer) +2.5 ≈g of Kex2 protease/mg of mGLP concatemer− 20 h
Lane 6 − mGLP (concatemer) +2.5 ≈g of Kex2 protease /mg of concatemer− 24 h
Lane 7 − mGLP (concatemer) +2.5 ≈g of Kex2 protease/mg of mGLP concatemer− 28 h
Lane 8 − mGLP (concatemer) +5 ≈g of Kex2 protease/mg of mGLP concatemer− 20 h
Lane 9 − mGLP (concatemer) +5 ≈g of Kex2 protease/mg of mGLP concatemer− 24 h
Lane 10 − mGLP (concatemer) +5 ≈g of Kex2 protease/mg of mGLP concatemer− 28 h
Lane 11 − mGLP (concatemer) +20 ≈g of Kex2 protease/mg of mGLP concatemer− 20 h
Lane 12 − mGLP (concatemer) +20 ≈g of Kex2 protease/mg of mGLP concatemer− 24 h
Lane 13 − mGLP (concatemer) +20 ≈g of Kex2 protease/mg of mGLP concatemer− 28 h
Lane 1: Molecular weight marker
Lane 2 − mGLP (concatemer) undigested - 16 h
Lane 3 − No loading
Lane 4 − mGLP (concatemer) +20 ≈g of Kex2 protease/mg of mGLP concatemer− 16 h
Lane 5 − mGLP (concatemer) +10 ≈g of Kex2 protease/mg of mGLP concatemer− 16 h
Lane 6 − mGLP (concatemer) +5 ≈g of Kex2 protease/mg of mGLP concatemer− 16 h
Sequences
| Number | Date | Country | Kind |
|---|---|---|---|
| 201721009672 | Mar 2017 | IN | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/IB2018/051842 | 3/20/2018 | WO | 00 |
